Immuno Oncology Assays Market Size, Share, Industry, Forecast and outlook (2023-2030)

Immuno Oncology Assays Market is segmented By Product Type (Consumables, Software), By Technology (Immunoassay, PCR, NGS, Flow Cytometry, others), By Application (Clinical Diagnostics, Research), By Assay type (Cell proliferation assays, Cell migration & invasion assays, Phagocytosis assays, Immune cell killing assays, others), By Indication (Colorectal Cancer, Lung Cancer, Melanoma, Bladder Cancer, others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Immuno Oncology Assays Market Overview

Immuno Oncology Assays Market size was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 12.19% during the forecast period (2022-2029). The immuno-oncology assay is a type of immunoassay primarily used for cancer diagnosis.

Immuno Oncology Assays Market - Strategic Insights

To know more insights into the Diagnostic Imaging Market, get our Sample Brochure

It is a procedure in which various analytes such as proteins, biomolecules, growth factors, cytokines, and chemokines are profiled by detecting and quantifying them simultaneously. This procedure majorly uses the body's natural defense system to target and destroy cancer cells. This assay is used as a tool for in vitro analysis to study the dynamic interactions between cancer cells & immune cells, intricate tumor microenvironment, perceiving immunoreactivity in a multitude of cell-based assays to predict mode of action and pharmacodynamics.

As per DataM Intelligence, Immuno Oncology Assays Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Immuno Oncology Assays Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Immuno Oncology Assays Market in the United States and Canada produces the utmost share. Whereas the European Immuno Oncology Assays Market is projected to continue its presence globally during the period of 2022- 2029.

Immuno Oncology Assays Market Dynamics and Trends

The immuno oncology assays market growth is driven by the increased demand for personalized medicine, the rising incidence of cancer, the growing adoption of targeted therapy, and the increasing significance of companion diagnostics in drug development.

Increasing prevalence of cancer cases coupled with the growing R&D of drugs expected to drive the market growth

Cancer is a complex disease that develops through multi-stage carcinogenesis involving multiple molecular pathway events. Thus, various challenges are associated with a cancer diagnosis, prognosis, and therapy. In this regard, a single marker is not helpful due to the complex nature of cancer. Moreover, each cancer differs from other cancer types in its molecular profile. Hence, immuno-oncology assays have been particularly significant in understanding cancer signatures and developing customized therapies.

According to World Health Organization, Cancer is the largest cause of mortality worldwide, accounting for approximately 10 million deaths in 2020, or nearly one in every six deaths. Breast, lung, colon, rectum, and prostate cancer are the most prevalent. Tobacco use, a high BMI, alcohol consumption, a lack of fruits and vegetables, and a lack of physical activity account for almost one-third of cancer fatalities. Infections that cause cancer, such as human papillomavirus (HPV) and hepatitis, account for around 30% of cancer cases in low- and lower-middle-income nations. More than 60% of new cancer cases occur in Africa, Asia, and Central and South America; 70% of global cancer deaths also occur in these regions. Thus, the growth in the incidence and prevalence of cancer has resulted in a need to conduct extensive research for diagnosis and treatment; immuno-oncology assays form an essential part of this research.

In addition, immuno-oncology assay holds enormous potential in the R&D of drugs to treat diseases, such as cancer and cardiovascular diseases. For instance, the xMAP multiplex assay provides a platform for cancer biomarker assays compatible with plasma, serum, cultured cells, and other biological samples. The American Association of Cancer Research (AACR) developed the multiplex immunoassay that helped examine acquired resistance to receptor tyrosine kinase (RTK) inhibitors. RTK is used as a target for drug development to treat cancer.

Requirement of high capital investment is expected to hamper the market growth

Major capital investments are required to discover, develop, and validate biomarkers. Additionally, diagnostic manufacturers are exposed to significant financial challenges due to the high drug attrition in clinical trials (with almost 30% of drugs failing in Phase III). To gain approval for in vitro diagnostics (IVD) from regulators, manufacturers need successful Phase III clinical trials, which depend on well-validated biomarker tests. Huge investments are required to run clinical trials and address stringent regulatory requirements, which affect the ability of small companies to develop biomarkers and severely affect innovation. Hence, along with the high amount of capital investments, the low cost-benefit ratio hinders the growth of the immuno-oncology assays market for biomarker detection.

Industry Analysis

The immuno oncology assays market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis, epidemiology etc.

COVID-19 Impact Analysis on Immuno Oncology Assays Market 

COVID-19 has profoundly impacted the number of patients undergoing cancer screening, diagnosis, and treatment. The increased pressure due to the growing rate of COVID-19 patients' hospitalization led to the re-profiling of many hospitals and departments, including oncology clinics, for treating patients with COVID-19. Consequently, many diagnostic and treatment procedures were canceled or postponed worldwide, including as many as 2.3 million cancer surgeries. Due to lockdown-related restrictions, delayed diagnosis and treatment of cancer patients are expected to increase cancer mortality rates. In the UK, in the next five years, the number of deaths from colorectal cancer and breast cancer is likely to increase by 15% and 9%, respectively. However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement.

Many patients affected by COVID-19 were people with malignancies. Research in this area is further undertaken to understand better the infection dynamics, which is expected to propel the cancer research field further. The shift in demand for research on COVID-19 and oncology has created a huge scope for testing solutions, such as assays and profiling panel testing products. This is further expected to drive the demand for immuno-oncology assays and instruments.

Immuno Oncology Assays Market Segment Analysis

The flow cytometry segment is expected to hold the largest market share in the immuno oncology assays market.

The flow cytometry segment accounted for the largest market share in 2021. Flow Cytometry is another method to analyze tumor cells. Immuno-Oncology tests are of various types, such as Immuno-Oncology tumor cell-based assays, Immuno-Oncology T-Cell based assays, Immuno Oncology natural killer cell-based assays, Immuno-Oncology macrophage assays, Immuno-Oncology Dendritic cell assays, Immuno-Oncology neutrophil assays.

There are numerous advantages of Flow cytometry. It allows the identification of cellular markers through surface or intracellular staining techniques. Different cell types can be identified using these markers, which help develop cell-specific therapies. For instance, CD4 is a standard marker for T cell subsets, which is involved in T cell activation that can also be found on natural killer cells, innate lymphoid cells, and macrophages. Furthermore, the numerous features of flow cytometry, such as its ability to characterize, count, and sort fluorescent-labeled cells based on fluorescence emission, make it easy for Flow Cytometry to be integrated into immuno-oncology. The ability to quantify and characterize specific subsets of cell populations, such as circulating T cells, enhances understanding of the immune system response. ​

 Immuno Oncology Assays Market Geographical Share

North American region is expected to hold the largest market share in the global immuno oncology assays market.

North America is the highest constituent among all the regions of the marker. The growth can be attributed to the rising number of cancer patients in the region and government support for research and development in the field of immunotherapy. Cancer is the second-leading cause of death in the United States. As per the American cancer society, in 2020, approximately 89,500 cancer cases were diagnosed, and around 9,300 cancer deaths in adolescents and young adults (AYAs) aged 15 to 39 years in the U.S. Favorable healthcare policies, high per capita healthcare spending, high healthcare infrastructure created the adoption of advanced cancer diagnostic technologies such as imaging in the U.S. Moreover, On June 24, 2021, Invivoscribe launched an Immune Biomarker Discovery grant program focused on supporting the development, validation and deployment of novel applications to use their distributed LymphoTrack NGS products and bioinformatics software. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

 Immuno Oncology Assays Companies and Competitive Landscape

Major key players in the immuno oncology assays market are Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc, Illumina, Inc, Merck Millipore, QIAGEN, Sartorius AG, Charles River Laboratories, Inc, PerkinElmer, Inc and Bio-Rad Laboratories, Inc.

Agilent Technologies, Inc.:

Overview:

Agilent Technologies Inc (Agilent) manufactures laboratory instruments, reagents, software, services, and consumables. Its product line includes, among other things, liquid and gas chromatography systems and components, microarray solutions, clinical and diagnostic tests, and automation systems. Biotechnology, pharmaceutical, contract research organizations (CROs) and contract manufacturing organizations (CMOS), chemical and energy, environmental and forensics, food, and other industries are served by the corporation. Agilent sells its products directly to customers, through distributors, manufacturers' agents, resellers, and online. It has R&D and manufacturing sites in the United States, the United Kingdom, Denmark, Germany, Italy, Japan, Malaysia, China, Singapore, and Australia.

­Product Portfolio:

Agilent NovoCyte Flow Cytometers: An advanced fluidic design gives the reproducibility, while also offering scheduled and automatic startup and shutdown, automatic cleaning cycles, and batch analysis and reporting.

The global immuno oncology assays market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Trending Topics

Oncology Information Systems Market

Oncology Based In-Vivo CRO Market

Oncology Information System Market

FAQ

Q1

Q3.  What are the recent trends affecting the immuno-oncology assays market?

A. Recent trends affecting the immuno-oncology assays market are the COVID-19 outbreak, rising incidence and prevalence of cancer, and the growing adoption of targeted therapy.